Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Guided Therapeutics (GTHP) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to 808.33%.

  • Guided Therapeutics' EBITDA Margin changed N/A to 808.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 1233.71%, marking a year-over-year increase of 41873400.0%. This contributed to the annual value of 30114.29% for FY2024, which is 265867300.0% down from last year.
  • As of Q3 2025, Guided Therapeutics' EBITDA Margin stood at 808.33%.
  • In the past 5 years, Guided Therapeutics' EBITDA Margin ranged from a high of 652.14% in Q2 2025 and a low of 53400.0% during Q4 2024
  • For the 5-year period, Guided Therapeutics' EBITDA Margin averaged around 12688.45%, with its median value being 3831.82% (2023).
  • As far as peak fluctuations go, Guided Therapeutics' EBITDA Margin skyrocketed by 137100000bps in 2022, and later tumbled by -518843800bps in 2024.
  • Guided Therapeutics' EBITDA Margin (Quarter) stood at 725.0% in 2021, then crashed by -5528bps to 40800.0% in 2022, then surged by 96bps to 1515.62% in 2023, then tumbled by -3423bps to 53400.0% in 2024, then surged by 98bps to 808.33% in 2025.
  • Its EBITDA Margin was 808.33% in Q3 2025, compared to 652.14% in Q2 2025 and 53400.0% in Q4 2024.